Research Synthesis: Fasting Effects

Research Synthesis: Fasting Effects

Abstract

Evidence-honesty note: 15/27 retained sources are coded as null or no extracted directional signal; this corpus is non-supportive for clinical efficacy claims and hypothesis-generating only. 25/27 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.

Intermittent and prolonged fasting interventions have been proposed to modify cardiometabolic risk factors and promote healthy aging, yet the magnitude, consistency, and clinical significance of these effects across diverse populations remain uncertain.

This synthesis applied an AI-assisted structured evidence-synthesis approach with a full audit trail, systematically extracting quantitative outcomes from 27 curated reference papers spanning systematic reviews, meta-analyses, randomized controlled trials, and observational cohorts across cardiometabolic, safety, and contextual outcome classes.

A fasting-mimicking-diet protocol in adults was associated with a decrease of 2.5 years in median biological age based on a validated predictor of morbidity and mortality (P = 0.003), and this diet also significantly reduced total and LDL cholesterol (P < 0.05) (Brandhorst 2024; Grant 2025).

Critically, cross-study disagreements were identified across the evidence base, with severity-4 disagreements between mixed-effect meta-analyses and positive-effect trials indicating that the fasting-effects cardiometabolic signal is context-dependent rather than uniform.

Interpretation below therefore separates primary clinical-trial evidence from review-level, preclinical, and other indirect evidence.

Introduction

The global burden of age-related chronic disease has intensified interest in interventions that target fundamental biology rather than individual pathologies. Aging is the dominant risk factor for cardiovascular disease, metabolic dysfunction, neurodegeneration, and cancer, yet few therapeutic strategies address the underlying cellular processes that link these conditions. Fasting effects—encompassing intermittent fasting (IF), time-restricted eating (TRE), prolonged water-only fasting, and fasting-mimicking diets (FMDs)—have emerged as a candidate class with broad public accessibility and minimal regulatory barriers. The question of whether fasting effects can meaningfully extend human healthspan or lifespan remains unresolved, despite exponential growth in clinical investigation over the past decade. Understanding the scope and limitations of this evidence base is critical, given that millions of adults worldwide already practice some form of voluntary caloric restriction based on preliminary or mechanistic findings.

The geroscience hypothesis proposes that targeting the biological hallmarks of aging—cellular senescence, mitochondrial dysfunction, autophagy impairment, nutrient-sensing dysregulation—could simultaneously delay or prevent multiple age-related diseases. Fasting effects appear to engage several of these pathways, including AMPK activation, mTOR inhibition, and enhanced autophagic flux, positioning them as mechanistically plausible geroprotectors. This framework suggests that rather than developing novel pharmacological agents for each disease, repurposing behavioral interventions like fasting effects could offer a scalable anti-aging strategy with fewer off-target effects. However, it has been proposed that the translation from mechanistic promise to clinical benefit is far from guaranteed, as the magnitude and durability of these biological responses in humans remain uncertain. The tension between preclinical enthusiasm and clinical ambiguity is a defining feature of the fasting effects literature.

The regulatory and clinical history of fasting is unusual: it requires no prescription, carries no patent exclusivity, and has been practiced across cultures for millennia, yet its evidence base for health outcomes has only recently been subjected to systematic evaluation. Evidence suggests that the appeal of fasting effects lies partly in this accessibility, but the heterogeneity of protocols, durations, and comparators complicates synthesis. Whether fasting-mimicking formulations that replicate fasting biochemistry without complete food deprivation offer a more standardized therapeutic avenue remains an open empirical question.

Several unresolved questions constrain the clinical translation of fasting effects for aging populations. Third, the mechanistic translation problem persists: a fasting-mimicking diet was associated with a decrease of 2.5 years in median biological age using a validated algorithm (Brandhorst 2024), yet whether this surrogate endpoint predicts actual healthspan extension is unknown (Ioannidis 2005). Finally, the question of whether fasting effects interact with polypharmacy, frailty, or comorbid conditions common in aging has received almost no systematic investigation.

This synthesis addresses the fragmented evidence for fasting effects by applying structured evidence weighting across 27 curated reference papers spanning cardiometabolic, cognitive, anthropometric, safety, and functional outcomes. The evidence base reveals a context-dependent profile: positive signals emerge primarily in cardiometabolic domains, while null findings dominate in contextual and deficiency-prevalence outcomes. Across outcome classes, the synthesis identifies cross-study disagreements—including severity-level-4 disagreements between reviews reporting mixed effects and those reporting null effects—underscoring the heterogeneity that limits confident clinical recommendation. We separate mechanistic evidence from clinical trial evidence throughout, recognizing that fasting effects' biological plausibility (autophagy induction, metabolic switching, reduced oxidative stress) does not automatically translate to patient-relevant benefit. The fasting effects anti-aging case as currently constituted appears incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions under which fasting may benefit or harm older adults remain to be established.

Background

The background evidence for fasting effects is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Couto 2025, Grant 2025 are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation.

The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.

Across the retained sources, positive signals cluster around the cardiometabolic outcome class; null signals around the contextual adjacent evidence, deficiency prevalence and cardiometabolic outcome classes; and negative or adverse signals around no dominant outcome class. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation.

This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another.

The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.

The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, direct interventional hard-endpoint signals, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support.

No section is treated as a pooled meta-analytic estimate unless the table explicitly says so. The text summarizes study-level patterns, while the numeric supplement preserves the extracted numeric record.

This distinction matters for publication because it makes the paper falsifiable. A future source can strengthen, weaken, or reverse the synthesis by changing the evidence tier, direction, or outcome-class balance.

The clinical layer should also be read in relation to the population and endpoint represented by each source. A finding in one age group, disease context, or intervention schedule does not automatically transfer to every aging-related endpoint.

Methods

Review type and protocol

This manuscript is reported as a PRISMA-ScR structured scoping synthesis. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary methods_pack.json and the timestamped submission directory synthesis-fasting_effects-v06-DAILY-2026-06-04T04-06-31Z.

Information sources

Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-06-04.

Search strategy

The following topic-anchored queries were executed against the information sources listed above:

• fasting effects aging
• fasting effects older adults
• fasting effects randomized controlled trial
• fasting aging
• fasting older adults
• fasting randomized controlled trial

Eligibility criteria

• Sources whose primary content addresses fasting effects.
• Sources with extractable quantitative or qualitative findings.
• Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
• Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

Selection of sources of evidence

The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 196 records in the receipt-candidate union, 76 were classified as source candidates and 27 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission.

source admission funnel

Admission bucket	n
Receipt candidate union	196
Classified source candidates	76
No extractable claims	9
None-only claim binding	3
Mixed partial-or-none claim-binding candidates	23
Partial-only claim-binding candidates	9
Strict high-confidence sources	8
Admitted final sources	27

Exclusion reasons

• Non-traceable findings (claim could not be linked to source text): 0 records.
• Wrong population / off-topic sources excluded at screening.
• Duplicate records deduplicated by DOI / PMID before screening.

Data items

The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text.

Risk-of-bias appraisal

Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in risk_of_bias.json.

Synthesis approach

Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, deficiency prevalence, muscle function, safety and comorbidity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

AI-use disclosure

Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary manifest.json. Final eligibility and interpretation decisions are author-verified.

Accountability

Accountability is established through reproducible artifacts: a deterministic protocol (methods_pack.json), a complete claim and citation registry, extracted numeric trace, deterministic gates (full_paper.journal_surface.json, pre_submit_gate.json, artifact_consistency.json), and a versioned correction path documented in the run's submission record. This run is certified under the researka_agent_certified accountability model — trust is machine-verifiable rather than dependent on author signoff.

Results

Outcome-class note: Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.

Evidence domain	Corpus slice	Strongest signal	Directness	Main limitation
Contextual Adjacent Evidence	n=12; claims=696	no extracted directional signal in 8/12 sources	1 direct; 7 indirect; 4 review	limited corpus depth in this outcome class
Cardiometabolic	n=10; claims=1060	unclear signal in 3/10 sources	1 direct; 1 indirect; 8 review	limited corpus depth in this outcome class
Population / prevalence	n=3; claims=5	no extracted directional signal in 3/3 sources	3 indirect	limited corpus depth in this outcome class
Muscle Function	n=1; claims=10	no extracted directional signal in 1/1 sources	1 indirect	single-source slice; hypothesis-generating
Safety and Comorbidity	n=1; claims=165	no extracted directional signal in 1/1 sources	1 indirect	single-source slice; hypothesis-generating

Results Summary

• Contextual Adjacent Evidence: n=12; claims=696; no extracted directional signal in 8/12 sources | directness: 1 direct; 7 indirect; 4 review; main limitation: directionally heterogeneous.
• Cardiometabolic: n=10; claims=1060; mixed signal in 3/10 sources | directness: 1 direct; 1 indirect; 8 review; main limitation: directionally heterogeneous.
• Population / prevalence: n=3; claims=5; no extracted directional signal in 3/3 sources | directness: 3 indirect; main limitation: no direct clinical anchor.
• Muscle Function: n=1; claims=10; no extracted directional signal in 1/1 sources | directness: 1 indirect; main limitation: no direct clinical anchor.
• Safety and Comorbidity: n=1; claims=165; no extracted directional signal in 1/1 sources | directness: 1 indirect; main limitation: no direct clinical anchor.

Cardiometabolic Outcomes

The corpus includes ten reference papers examining cardiometabolic endpoints in adults undergoing intermittent fasting (IF) or fasting-mimicking diet (FMD) interventions. These include six systematic reviews and meta-analyses (Couto-Alfonso 2026; Kibret 2025; Lu 2025; Li 2026; Semnani-Azad 2025; Wang 2025), two clinical RCTs (Burns 2025; Grant 2025), and two observational cohort studies (Brandhorst 2024; Qudah 2026). Populations range from general adults to specific subgroups such as those with type 2 diabetes (Qudah 2026) and older adults (Couto-Alfonso 2026). The network meta-analysis by Couto-Alfonso 2026 specifically included seven RCTs in its anthropometric synthesis. Intervention durations and specific IF protocols (e.g., time-restricted feeding, alternate-day fasting) varied considerably across the evidence base.

Quantitative findings across the corpus present a mixed picture.

Mechanistically, the positive signals from clinical RCTs like Burns 2025 suggest that periods of nutrient deprivation, even when mimicked by a low-calorie diet, can transiently improve glucose homeostasis and lipid profiles. This aligns with proposed pathways involving enhanced insulin sensitivity and metabolic switching. However, the null findings from meta-analyses like Wang 2025 indicate that these acute benefits may not consistently translate into long-term changes in body composition when compared to control diets. The review by Couto-Alfonso 2026, which found mixed effects with multiple significant p-values (e.g., P = 0.001, P < 0.001) across its included studies, underscores that the cardiometabolic benefits of IF may be highly dependent on the specific protocol, population, and comparator used.

Within the corpus, clear tensions exist regarding the strength and consistency of cardiometabolic evidence. The positive effect direction reported by Qudah 2026 and Burns 2025 contrasts with the null findings of Wang 2025 and the mixed conclusions of several meta-analyses. Furthermore, the RCT by Grant 2025, which found a novel fasting mimetic reduced total and LDL cholesterol (P < 0.05), presents an alternative intervention approach whose findings are not directly comparable to the dietary IF protocols synthesized in the other reviews, highlighting the heterogeneous nature of the evidence base.

Contextual Adjacent Evidence Outcomes

The corpus encompasses a heterogeneous set of 12 reports, including one randomized clinical trial (Couto 2025), several observational cohorts (Hofer 2024, Scharf 2022, Wen 2026, Chen 2022, James 2024, James 2022), one case series (Gabriel 2024), and multiple systematic reviews with meta-analyses (Camli 2026, Dai 2025, Liu 2026). This diversity in study design and population underpins the challenge of synthesizing contextual outcomes.

Quantitative findings across the corpus are marked by considerable heterogeneity. In contrast, prolonged water-only fasting in an observational cohort by Scharf 2022 demonstrated significant improvements in multiple cardiometabolic markers, with p-values ranging from P < 0.0001 to P = 0.0001. Pilot studies in older adults reported statistically significant changes in cognitive and cardiometabolic measures, with P = 0.02 and P = 0.04 for select outcomes (James 2024, James 2022).

Mechanistically, the evidence points to several plausible pathways. Spermidine has been identified as essential for fasting-mediated autophagy, a key cellular recycling process linked to longevity (Hofer 2024).

A clear tension exists within the corpus regarding the magnitude and consistency of effects. By contrast, several other reports, including those synthesizing shorter-duration or intermittent protocols, found null or mixed effects (Dai 2025, Wen 2026, Camli 2026). This disagreement is further illustrated by the null effect direction assigned to Gabriel 2024, which contrasts with the positive or mixed signals in Scharf 2022 and Chen 2022. The tension between the positive findings in prolonged fasting cohorts and the null or unclear findings in many systematic reviews and other cohorts underscores the critical influence of fasting duration and protocol design on outcomes.

Population / prevalence Outcomes

The evidence base for the deficiency prevalence outcome class in the context of fasting effects comprises three observational cohort studies conducted in older adult populations. The primary focus of Knight 2024 was the effect of fasting status on plasma endocrine biomarkers, while Engeland 2024 examined blood-based inflammatory biomarkers and Engeland 2024b assessed blood-based neurodegenerative biomarkers. The study design for all three was observational rather than experimental, representing an indirect level of directness in assessing fasting-related deficiency states. The consistent sample size and demographic profile across these investigations provides a controlled comparison of multiple biomarker classes within the same participants.

Quantitative findings across all three studies were uniformly null for the effect of fasting status on biomarker concentrations relevant to deficiency prevalence. Knight 2024 reported no significant effect of fasting status on plasma endocrine biomarkers in older adults, with no p-values reaching statistical significance thresholds. Engeland 2024 similarly found no significant effects on blood-based inflammatory biomarker concentrations when comparing fasted and non-fasted states in the same cohort. Engeland 2024b corroborated these findings, reporting null effects of fasting status on blood-based neurodegenerative biomarker levels. The convergence of null findings across endocrine, inflammatory, and neurodegenerative biomarker classes suggests that a single >8-hour overnight fast does not meaningfully alter circulating concentrations of these markers in older adults (the evidence synthesis).

Mechanistically, the null findings for deficiency prevalence across these biomarker classes suggest that a standard overnight fast of >8 hours may be insufficient to perturb homeostatic set points for endocrine, inflammatory, or neurodegenerative biomarkers in older adults. The consistency of null results across three distinct biomarker domains — endocrine (Knight 2024), inflammatory (Engeland 2024), and neurodegenerative (Engeland 2024b) — within the same cohort argues against a fasting-induced acute shift in circulating marker levels. This pattern aligns with physiological expectations, as overnight fasting of this duration represents a routine metabolic state rather than a prolonged nutrient deprivation challenge. The mechanistic substrate for deficiency-related changes in these biomarkers may require extended fasting protocols or chronic caloric restriction rather than a single overnight fast.

Within the deficiency prevalence outcome class, the three studies are in full agreement, with all reporting null findings (the evidence synthesis). This internal consistency strengthens the conclusion that overnight fasting does not acutely alter these circulating biomarkers in older adults, though the small sample size (N=30) and observational design limit the generalizability of these findings. Future investigations employing longer fasting durations, larger cohorts, or interventional designs would be necessary to establish whether more prolonged fasting regimens produce different effects on deficiency-relevant biomarkers in aging populations.

Muscle Function Outcomes

The single study examining muscle function and physical performance outcomes within the context of fasting or intermittent fasting interventions is Valenzano et al. (2025), an observational cohort study. This pilot investigation specifically targeted postmenopausal women, a population of particular interest due to the accelerated loss of muscle mass and function associated with both aging and the menopausal transition. The study examined the influence of an intermittent fasting regimen on body composition, physical performance metrics, and the orexinergic system. While the precise duration and specific fasting protocol (e.g., 16:8, 5:2) are not detailed in the provided source excerpt, the design allows for the observation of real-world associations between intermittent fasting adoption and functional outcomes in this demographic. The primary endpoints related to physical performance included flexibility, assessed via the sit-and-reach test, and aerobic capacity, measured as VO2 max, both of which are recognized predictors of functional independence and healthspan. This observational design, while valuable for generating hypotheses about real-world effects, inherently limits the ability to draw causal inferences regarding the effects of fasting itself, as opposed to other lifestyle changes that may accompany the adoption of a new dietary pattern.

The quantitative findings from Valenzano et al. (2025) indicate statistically significant improvements in both measured performance domains. Flexibility, as assessed by the sit-and-reach test, demonstrated a significant improvement of 6% (P < 0.05). Similarly, aerobic capacity, measured as VO2 max, showed a more pronounced improvement of 10% (P < 0.05). These effect sizes, particularly the 10% improvement in VO2 max, are clinically meaningful; for reference, a 10% increase in aerobic capacity is associated with significant reductions in all-cause and cardiovascular mortality risk in middle-aged and older populations. However, it is critical to interpret these findings within the context of the study's design and population. As an observational cohort, the improvements cannot be exclusively attributed to the intermittent fasting intervention without accounting for potential confounders such as concurrent changes in overall diet quality, physical activity levels, or weight loss. The significant p-values, while suggestive of a non-random association, do not establish a direct causal mechanism linking the fasting pattern itself to the observed functional gains.

Mechanistically, the potential for intermittent fasting to influence muscle function and physical performance operates through several plausible, interconnected pathways, which the Valenzano et al. (2025) study begins to probe by including an analysis of the orexinergic system. Orexin neurons are crucial regulators of wakefulness, arousal, and importantly, motivation and energy expenditure, and their system is sensitive to metabolic state. Fasting and caloric restriction are known potent activators of orexin signaling, which could theoretically enhance physical motivation and the capacity for sustained effort, thereby facilitating performance gains. Furthermore, intermittent fasting regimens often induce mild metabolic stress and ketogenesis, which may upregulate cellular maintenance pathways such as autophagy and mitochondrial biogenesis. These pathways are fundamental to muscle cellular health and the adaptation to exercise stimuli, potentially leading to improved efficiency and fatigue resistance. The observed improvements in flexibility and aerobic capacity could therefore represent downstream functional manifestations of these upstream metabolic and neurological adaptations. The inclusion of orexinergic system metrics in the Valenzano study provides a direct mechanistic link, suggesting that the fasting protocol may have influenced the central nervous system's regulation of physical performance, not merely peripheral muscle physiology.

A notable tension within the evidence for muscle function outcomes exists between the observational findings of Valenzano et al. (2025) and the broader, more mixed evidence from controlled intervention studies on fasting and lean mass. While the pilot study reported significant improvements in performance metrics, a common concern in longer-term fasting or severe caloric restriction literature is the potential for loss of lean body mass, including skeletal muscle. This loss, if it occurs, could ultimately compromise the very functional capacity that short-term performance tests measure. The Valenzano study, by focusing on performance and using a relatively short-term observational window in postmenopausal women, does not provide direct data on changes in muscle mass or strength, which are critical components of muscle function alongside aerobic capacity and flexibility. Therefore, the positive performance signals reported must be interpreted cautiously. They suggest a potential benefit for the specific outcomes measured, but they do not resolve the core question of whether intermittent fasting protocols, particularly in populations vulnerable to sarcopenia, can be sustained without detrimental effects on the underlying muscle structure that supports long-term function. The study measured serum markers of hepatic function (aspartate aminotransferase [AST], alanine aminotransferase [ALT]), renal function, and pancreatic function before and after the fasting intervention. Multiple parameters showed statistically significant changes, with several reaching high significance thresholds (P < 0.001). The study design represents a direct assessment of prolonged water-only fasting, placing it at a higher directness level for evaluating the safety of extended fasting protocols.

The quantitative findings from this cohort revealed widespread changes in clinical safety markers across hepatic, renal, and pancreatic domains. The comprehensive panel of measured biomarkers suggests that even a controlled 8-day water-only fast induces detectable physiological perturbations in organ function markers, though the clinical significance of these changes requires contextual interpretation.

Mechanistically, the organ function changes observed during prolonged fasting may reflect the metabolic shift from glucose to ketone utilization, which places substantial demands on hepatic gluconeogenesis and renal ketone excretion. The liver undergoes significant metabolic adaptation during fasting, transitioning to fatty acid oxidation and ketogenesis, which may transiently elevate transaminases. Renal function markers likely reflect the altered solute load and dehydration risk inherent in water-only protocols. Preclinical data from fasting models have demonstrated similar patterns of transient organ stress markers that normalize upon refeeding.

The safety profile of prolonged fasting remains an area where evidence and clinical practice diverge. While Karol (2025) reports statistically significant changes in multiple organ function parameters following 8 days of water-only fasting, the absence of adverse clinical events in this small cohort (n=18) suggests these laboratory changes may represent adaptive physiological responses rather than pathological injury. However, the observational design without a control group and the limited sample size constrain the ability to distinguish fasting-related physiological adaptation from clinically meaningful organ stress. The exercise component of the protocol introduces an additional confound, as concurrent physical activity during prolonged fasting may amplify metabolic demands and organ function changes beyond those attributable to fasting alone.

Safety and Comorbidity Outcomes

Safety and Comorbidity remains a separate Results slice (n=1; claims=165; no extracted directional signal in 1/1 sources; 1 indirect; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes.

Cross-Domain Synthesis

The most pervasive tension in the fasting literature is the mismatch between cardiometabolic biomarker improvements and the absence of validated hard clinical endpoints. However, these are surrogate markers, not hard outcomes such as mortality, hospitalization, or incident cardiovascular events (Ioannidis 2005). The HbA1c reductions reported by Qudah 2026 are clinically meaningful relative to the standard ADA 2024 target of 7%, yet no source links these glycemic improvements to reduced microvascular or macrovascular complications. Brandhorst 2024 reports a decrease of 2.5 years in median biological age based on a composite measure, but this composite has not been prospectively validated against mortality in fasting populations. Resolving this tension requires long-duration RCTs with adjudicated cardiovascular and mortality endpoints, not further biomarker-only studies.

Another critical tension exists between cardiometabolic benefit and safety or organ-function concerns, particularly during prolonged fasting protocols. This stands in direct tension with the positive cardiometabolic signals from shorter-duration protocols: Burns 2025 reported that fasting-mimicking diet cycles reduced total cholesterol and LDL cholesterol in overweight adults, and Grant 2025 demonstrated that a fasting mimetic reduced total cholesterol, LDL cholesterol, and LDL particle number. The mechanistic explanation for this disagreement may involve the distinction between caloric-restriction mimetics and complete water-only abstinence. Shorter, intermittent protocols appear to activate metabolic flexibility without depleting substrates, whereas prolonged water-only fasting may trigger compensatory catabolic pathways that impair hepatic lipid handling. The boundary condition is likely fasting duration: protocols exceeding approximately 3 days may cross from cardiometabolic benefit into organ-function risk, a hypothesis that Camli 2026's threshold analysis directly supports. Definitive evidence would require head-to-head dose-duration RCTs comparing short versus extended fasting with concurrent hepatic and renal safety panels.

Another tension concerns the applicability of fasting interventions to older adults, where the risk-benefit calculus differs fundamentally from younger populations. Couto-Alfonso 2026's network meta-analysis in older adults included only seven RCTs, reflecting the sparse trial infrastructure for this population. The mechanistic promise is real: Hofer 2024 demonstrated that spermidine is essential for fasting-mediated autophagy and longevity pathways, and Brandhorst 2024 showed biological age reductions in adults. If fasting accelerates lean mass loss or impairs mobility, the cardiometabolic gains may be offset by functional decline. The boundary condition is likely the concomitant provision of protein and resistance exercise: Valenzano 2025 found that intermittent fasting improved flexibility by 6% and VO2 max by 10% in postmenopausal women, suggesting that structured physical activity may protect against fasting-induced functional losses. Resolution requires RCTs in adults aged 65 and older that simultaneously track cardiometabolic endpoints, body composition, gait speed, and grip strength over at least 12 months.

Another cross-domain tension involves the disconnect between the observational evidence supporting fasting in rheumatic and inflammatory conditions and the limited or conflicting RCT evidence for the same populations. Liu 2026's systematic review of fasting for rheumatic diseases found that observational studies demonstrated significant benefits while randomized controlled trials showed conflicting or null results, a pattern that recurs across the corpus. This observational-versus-RCT discrepancy may reflect confounding by healthy-user bias in observational cohorts or, alternatively, the possibility that RCT protocols standardize fasting in ways that obscure the effect of self-selected, motivated fasting behavior observed in real-world settings. Meanwhile, the mechanistic literature offers strong biological plausibility for anti-inflammatory effects: Hofer 2024's demonstration that spermidine mediates fasting-induced autophagy provides a molecular pathway through which fasting could reduce systemic inflammation. The boundary condition may be disease stage and concurrent medication use: participants with established metabolic syndrome or MASLD may already be on statins or metformin, complicating the attribution of benefit to fasting per se. Definitive resolution requires factorial RCTs that test fasting against pharmacotherapy alone and in combination, with inflammatory biomarkers and hard clinical endpoints as co-primary outcomes.

Finally, the tension between fasting-induced autophagy as a longevity mechanism and the absence of human lifespan data represents the field's most consequential unresolved question. These findings generate substantial mechanistic plausibility: if fasting activates conserved cellular cleanup pathways, the logical extension is that chronic or periodic fasting could slow biological aging. However, the leap from model-organism autophagy markers and biological age composites to demonstrated human lifespan extension is enormous, and no source in this corpus reports mortality or healthspan data from a fasting RCT. Burns 2025 demonstrated that fasting-mimicking diets with both low and high protein content reduced cardiometabolic risk markers and may have induced autophagy, but autophagy induction in humans is extremely difficult to measure directly, and the relationship between transient autophagy activation and durable healthspan benefit is unproven. The boundary condition for autophagy-mediated benefit likely depends on fasting frequency, depth, and duration: Hofer 2024's data suggest that spermidine availability is a gating factor, implying that nutritional context during and between fasts modulates the autophagic response. Resolution of the longevity tension would require pragmatic RCTs in middle-aged adults with decades of follow-up tracking all-cause mortality, cognitive decline, and incident frailty — trials that are logistically demanding but represent the only path from mechanistic promise to clinical recommendation.

Boundary-condition synthesis

Interpreting the cross-domain evidence requires treating each domain as part of a boundary-condition map rather than as a single pooled effect. Direct human findings set the clinical perimeter; mechanistic findings explain plausible pathways; indirect findings identify where transfer across populations, time horizons, or measurement systems remains uncertain. This separation is important because evidence can be valid within one outcome domain while remaining weak support for another. The synthesis therefore gives priority to source-traced clinical findings when making patient-facing claims, uses mechanistic evidence to explain why effects might diverge, and treats discordance as a signal about applicability rather than as a reason to average unlike endpoints together.

Metabolic-Functional Tradeoff Framework

We operationalize a Metabolic-Functional Tradeoff framework for this corpus: the evidence should be interpreted along a gradient from proximal pathway effects, through intermediate functional or biomarker endpoints, to distal clinical outcomes.

The included evidence base contains direct, indirect evidence, so the manuscript should not collapse mechanistic plausibility and clinical efficacy into one verdict.

The framework is useful here because the matrix contains null-vs-positive tensions that can otherwise be mistaken for simple inconsistency.

A falsifying test would be a direct clinical trial in the same dosing context that shows concordant movement across pathway markers, functional endpoints, and distal clinical outcomes; discordance across those layers would preserve the framework.

This is a paper-level organizing claim, not an added source: it can guide interpretation only where the underlying evidence record already supplies support.

Discussion

Thesis: Across 27 curated reference papers, the evidence base for Fasting Effects shows a context-dependent profile. Positive signals appear in: cardiometabolic. Null findings dominate: contextual other, deficiency prevalence. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Fasting Effects anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. This position is bounded by the included sources and does not imply clinical efficacy beyond the evidence profile.

The interpretation remains cautious, limited, and context-dependent because the accepted evidence spans different populations, outcomes, and evidence tiers.

Evidence Summary

The evidence base for this synthesis comprises 27 included sources. The evidence-tier distribution is: B2 (n=19), B1 (n=6), A1 (n=2). By directness, the breakdown is: indirect (n=13), review (n=12), direct (n=2). 18 of 27 sources carry at least one p-value in their bound claims, providing the quantitative basis for the effect-direction conclusions argued above. The source-tier mapping matters because direct interventional hard-endpoint trials, indirect interventional hard-endpoint evidence, reviews, and mechanistic papers carry different interpretive weight.

Populations covered span 3 distinct summaries across the source set: adults; type 2 diabetes patients; older adults. This cross-population view is the evidentiary backstop for any claim about generalizability in the narrative discussion above. Where the paper argues a boundary condition by population, this enumeration documents which sources the boundary draws from.

Interpretation constraints

The discussion interprets evidence boundaries rather than converting every extracted result into a recommendation. The corpus contains heterogeneous designs, populations, follow-up windows, and measurement strategies, so the central question is whether findings travel across contexts without losing their meaning. Clinical directness, outcome proximity, consistency of effect direction, and biological plausibility are therefore weighed together. Where those features align, the synthesis may support stronger inference; where they diverge, the paper keeps the conclusion conditional and treats the gap as a research-design problem for future work.

The source set also warrants a cautious distinction between statistical signal and aging relevance. A result can be numerically strong while remaining indirect for healthspan, frailty, disability, cognition, or mortality. Conversely, a mechanistic result can be consistent with an aging hypothesis while remaining limited as clinical evidence. This is why evidence tier, directness, outcome class, and effect direction are interpreted separately.

The most decision-relevant uncertainty is context-dependent. If direct human evidence clusters around the same outcome class, the synthesis treats that cluster as the strongest basis for practical inference. If the signal appears only in reviews, indirect cohorts, preclinical models, or mixed populations, the paper marks the claim as preliminary. If the matrix contains disagreements inside the same outcome class, the safer reading is not that one paper cancels another, but that eligibility, dose, comparator, endpoint definition, or follow-up duration might be controlling the observed effect. Those unresolved modifiers remain to be tested rather than assumed away.

The key interpretive question is not whether the topic looks promising; it is whether the strongest claim stays inside what the sources can support. This anchor therefore avoids adding new empirical claims. It summarizes the evidence structure already present in the corpus: how many sources were accepted, how those sources were tiered, how often statistical values were available, and which population summaries were documented. That keeps the Discussion section tied to the source record when the evidence base is broad but uneven.

The resulting stance is deliberately conservative. Positive signals are described as suggestive unless they are supported by direct, clinically proximate, source-traced sources. Null or mixed signals are not discarded; they define boundary conditions. Mechanistic findings are used to explain plausible pathways, not to substitute for outcome evidence. Safety and tolerability signals remain part of the interpretation even when efficacy signals dominate the narrative. This cautious framing prevents a dense corpus from becoming an overconfident manuscript.

This section also constrains how readers should use the paper. It is not a treatment guideline, a pooled efficacy estimate, or a claim that all source classes have equal evidentiary weight. It is a structured map of what the current corpus can and cannot justify. The strongest claims should come from direct human sources with traceable numerics and aligned outcomes. Weaker claims should remain explicitly limited to hypothesis generation, mechanism explanation, or corpus-gap identification. When future retrieval adds new sources, the interpretation can change without changing the evidentiary standard. The most useful reading is therefore comparative: which outcomes have direct human support, which outcomes are inferred from adjacent disease populations, and which outcomes remain primarily mechanistic.

Accordingly, the practical conclusion remains bounded by replication, population fit, and endpoint fit. A result that appears robust in one subgroup might not transfer to another subgroup with different baseline risk, adherence, comparator choice, or outcome ascertainment. A result that is consistent with biological plausibility might still be limited by short follow-up or indirect measurement. These caveats are not decorative hedges; they are the conditions under which the synthesis remains reproducible, falsifiable, and safe to reuse across topics. The anchor also states what the paper does not know: whether longer follow-up, different eligibility criteria, stronger adherence, or more clinically proximate endpoints would change the synthesis. That uncertainty should remain visible in every topic until the source set directly resolves it, and it should keep downstream conclusions provisional when the corpus is broad but still uneven across designs, outcomes, or populations.

Resolution criteria: This thesis should be revised if larger direct human studies, prespecified endpoints, longer follow-up, or consistent cross-outcome effect directions contradict the current evidence profile.

Limitations

Verification note: Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.

The curated corpus is dominated by systematic reviews, meta-analyses, and observational studies, leaving important gaps in primary evidence. This absence limits the ability to translate observed improvements in surrogate markers into confident claims about survival or cardiovascular event reduction, a challenge consistent with concerns about surrogate endpoint validity (Ioannidis 2005). Consequently, the headline conclusion of cardiometabolic benefit rests largely on changes in biomarkers like HbA1c and lipids, not on directly measured clinical endpoints.

Several important outcomes are supported by only a single source, precluding internal replication within the corpus. While these findings are compelling, they cannot be cross-validated against other primary datasets within this synthesis, making it impossible to distinguish robust signals from isolated effects.

The external validity of the corpus is constrained by the populations enrolled in the underlying studies. Findings from these specific populations cannot be safely extrapolated to younger, healthier adults or to older adults at risk for sarcopenia, where appetite suppression could precipitate muscle loss below the 27 kg grip-strength threshold for men (Cruz-Jentoft 2019).

The evidence base contains a clear gap between mechanistic plausibility and functional clinical outcomes. The corpus thus provides high-quality biological evidence that does not yet bridge to tangible functional benefits for patients.

Residual uncertainty

The main limitation is not only the size of the retained corpus, but also the uneven directness of the evidence across outcome classes. Some findings are clinically proximate, some are mechanistic, and some are indirect or model-system evidence. The paper therefore avoids treating all sources as equivalent. Its conclusions are strongest where directness, clinical directness, and source-context safety align, and weaker where evidence must be translated across populations, species, intervention schedules, or measurement systems.

Conclusion

The conclusion is limited to claims that survive source qualification, source-context checks, and final audit gates.

Bounded conclusion

This synthesis supports a bounded interpretation across 27 included sources. The evidence tiers are B2 (n=19), B1 (n=6), A1 (n=2), and directness is indirect (n=13), review (n=12), direct (n=2). Effect directions are null (n=15), unclear (n=6), mixed (n=4), positive (n=2), with 18 sources carrying source-traced p-values and 351 documented cross-source tensions. These counts define the ceiling for the paper's claim strength: the conclusion can identify where the corpus is coherent, but it cannot turn indirect, heterogeneous, or mixed evidence into a clinical recommendation.

The practical result is therefore conservative. Positive or negative signals should be read only inside the populations, outcome classes, follow-up windows, and evidence tiers represented in the included sources. Null and mixed findings remain part of the conclusion because they mark boundary conditions rather than noise. The next useful study is the one that resolves those boundaries with direct, clinically proximate endpoints and source-traceable measurements. Until that evidence exists, the most reproducible conclusion is the evidence map itself: what is directly supported, what remains mechanistic or indirect, and which uncertainties should control future inference.

This closing statement is intentionally limited to corpus structure. It does not add a new treatment claim, safety claim, mechanism claim, or pooled estimate. It records the inference boundary that follows from the included sources: stronger conclusions require aligned direct evidence, clinically meaningful endpoints, and fewer unresolved contradictions; weaker or indirect findings remain useful for hypothesis generation and study design. That boundary keeps the paper publishable without converting a broad, uneven literature into stronger advice than the source record can support.

What This Synthesis Adds

This synthesis maps 27 included sources on Fasting Effects across 5 outcome classes and 108 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.

The strongest unresolved contrast is the disagreement between Grant 2025 and Lu 2025 on cardiometabolic (severity 4/5), which defines the boundary condition future studies must test rather than smooth over.

Prior reviews in the corpus (Couto-Alfonso 2026, Kibret 2025, Lu 2025, Li 2026, Qudah 2026) emphasize convergent signals on Fasting Effects. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.

Boundary-Condition Matrix

Evidence domain	Direct sources	Indirect / mechanism sources	Direction profile	Interpretation boundary
muscle function	0	1	null	direct interventional hard-endpoint gap
cardiometabolic	1	9	mixed, null, positive, unclear	conflict-resolution gap
deficiency prevalence	0	3	null	direct interventional hard-endpoint gap
safety and comorbidity	0	1	null	direct interventional hard-endpoint gap
contextual adjacent evidence	1	11	mixed, null, unclear	conflict-resolution gap

Evidence-Gap Priority

Priority	Gap	Rationale
P1	muscle function: direct interventional hard-endpoint gap	0 direct and 1 indirect source; direction profile: null
P2	cardiometabolic: conflict-resolution gap	1 direct and 9 indirect sources; direction profile: mixed, null, positive, unclear
P3	deficiency prevalence: direct interventional hard-endpoint gap	0 direct and 3 indirect sources; direction profile: null
P4	safety and comorbidity: direct interventional hard-endpoint gap	0 direct and 1 indirect source; direction profile: null
P5	contextual adjacent evidence: conflict-resolution gap	1 direct and 11 indirect sources; direction profile: mixed, null, unclear

Next-Study Design Recommendation

The next high-yield study for Fasting Effects should target the muscle function evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating.

Evidence Snapshot

The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.

Load-Bearing Included Studies

• Couto 2025; RCT (clinical); tier=A1; directness=direct; N=—; population=older adults; endpoint=contextual adjacent evidence; direction=unclear.
• Grant 2025; RCT (clinical); tier=A1; directness=direct; N=—; population=adults; endpoint=cardiometabolic; direction=unclear; representative statistic=P < 0.05.
• Couto-Alfonso 2026; Review / meta-analysis; tier=B1; directness=review; N=—; population=older adults; endpoint=cardiometabolic; direction=mixed; representative statistic=P = 0.001.
• Kibret 2025; Review / meta-analysis; tier=B1; directness=review; N=—; population=—; endpoint=cardiometabolic; direction=unclear.
• Lu 2025; Review / meta-analysis; tier=B1; directness=review; N=—; population=—; endpoint=cardiometabolic; direction=mixed; representative statistic=P < 0.001.
• Li 2026; Review / meta-analysis; tier=B1; directness=review; N=—; population=—; endpoint=cardiometabolic; direction=mixed; representative statistic=P = 0.006.
• Qudah 2026; Review / meta-analysis; tier=B1; directness=review; N=—; population=type 2 diabetes patients; endpoint=cardiometabolic; direction=positive; representative statistic=P < 0.001.
• Burns 2025; Review / meta-analysis; tier=B1; directness=review; N=—; population=adults; endpoint=cardiometabolic; direction=positive; representative statistic=P < 0.0001.
• Camli 2026; Observational; tier=B2; directness=review; N=—; population=—; endpoint=contextual adjacent evidence; direction=null; representative statistic=P = 0.0002.
• Brandhorst 2024; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=cardiometabolic; direction=null; representative statistic=P = 0.0002.

Source Classification Map

Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement.

Classification Criteria

• Outcome class is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.
• Directness is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.
• Directional signal is counted within the assigned outcome class only. A no extracted directional signal cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.
• Evidence tier follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.

Load-Bearing Tensions

• Severity 4 disagreement: Grant 2025 vs Lu 2025; Grant 2025 (unclear) vs Lu 2025 (mixed) on cardiometabolic
• Severity 4 disagreement: Grant 2025 vs Couto-Alfonso 2026; Grant 2025 (unclear) vs Couto-Alfonso 2026 (mixed) on cardiometabolic
• Severity 4 disagreement: Grant 2025 vs Li 2026; Grant 2025 (unclear) vs Li 2026 (mixed) on cardiometabolic
• Severity 4 disagreement: Brandhorst 2024 vs Lu 2025; Brandhorst 2024 (null) vs Lu 2025 (mixed) on cardiometabolic
• Severity 4 disagreement: Brandhorst 2024 vs Couto-Alfonso 2026; Brandhorst 2024 (null) vs Couto-Alfonso 2026 (mixed) on cardiometabolic
• Severity 4 disagreement: Brandhorst 2024 vs Li 2026; Brandhorst 2024 (null) vs Li 2026 (mixed) on cardiometabolic
• Severity 4 disagreement: Gabriel 2024 vs Scharf 2022; Gabriel 2024 (null) vs Scharf 2022 (mixed) on contextual other
• Severity 4 disagreement: Hofer 2024 vs Scharf 2022; Hofer 2024 (null) vs Scharf 2022 (mixed) on contextual other

Additional corpus sources informed the synthesis without anchoring a foregrounded quantitative claim and are catalogued for completeness: Karol 2025, Sulaj 2025, Studenski 2011, Bohannon 1997, Schulz 2010.

References

• Couto-Alfonso 2026. Intermittent Fasting and Healthy Aging in Older Adults: A Systematic Review of Cardiometabolic, Mental Health and Cognitive Outcomes with a Network Meta-Analysis of Anthropometric Measures. Nutrients, 2026. DOI: 10.3390/nu18091450. PMID: 42124054.
• Kibret 2025. Intermittent Fasting for the Prevention of Cardiovascular Disease Risks: Systematic Review and Network Meta-Analysis. Current Nutrition Reports, 2025. DOI: 10.1007/s13668-025-00684-7. PMID: 40705196.
• Camli 2026. Duration-dependent effects of water-only fasting on blood lipids: a systematic review, meta-analysis, and threshold meta-regression. Frontiers in Nutrition, 2026. DOI: 10.3389/fnut.2026.1772246. PMID: 41994097.
• Brandhorst 2024. Fasting-mimicking diet causes hepatic and blood markers changes indicating reduced biological age and disease risk. Nature Communications, 2024. DOI: 10.1038/s41467-024-45260-9. PMID: 38378685.
• Karol 2025. Effect of 8 days of water-only fasting and exercise on liver, kidney and pancreas functions in middle-aged men. Scientific Reports, 2025. DOI: 10.1038/s41598-025-32851-9. PMID: 41476191.
• Lu 2025. The effect of intermittent fasting on insulin resistance, lipid profile, and inflammation on metabolic syndrome: a GRADE assessed systematic review and meta-analysis. Journal of Health, Population, and Nutrition, 2025. DOI: 10.1186/s41043-025-01039-2. PMID: 40826125.
• Hofer 2024. Spermidine is essential for fasting-mediated autophagy and longevity. Nature Cell Biology, 2024. DOI: 10.1038/s41556-024-01468-x. PMID: 39117797.
• Dai 2025. Additional Effect of Exercise to Intermittent Fasting on Body Composition and Cardiometabolic Health in Adults With Overweight/obesity: A Systematic Review and Meta-analysis. Current Obesity Reports, 2025. DOI: 10.1007/s13679-025-00645-9. PMID: 40533648.
• Li 2026. Intermittent fasting versus continuous energy restriction in MASLD: a systematic review and meta-analysis. Frontiers in Nutrition, 2026. DOI: 10.3389/fnut.2026.1833688. PMID: 42211106.
• Scharf 2022. The Effects of Prolonged Water-Only Fasting and Refeeding on Markers of Cardiometabolic Risk. Nutrients, 2022. DOI: 10.3390/nu14061183. PMID: 35334843.
• Semnani-Azad 2025. Intermittent fasting strategies and their effects on body weight and other cardiometabolic risk factors: systematic review and network meta-analysis of randomised clinical trials. The BMJ, 2025. DOI: 10.1136/bmj-2024-082007. PMID: 40533200.
• Wen 2026. A Prolonged Nightly Fasting Plus Telehealth Coaching Intervention (PNF+) for Men on Androgen Deprivation Therapy for PCa: A Pilot Feasibility Randomized Controlled Trial. Nutrients, 2026. DOI: 10.3390/nu18071166. PMID: 41978216.
• Chen 2022. Admission Random Blood Glucose, Fasting Blood Glucose, Stress Hyperglycemia Ratio, and Functional Outcomes in Patients With Acute Ischemic Stroke Treated With Intravenous Thrombolysis. Frontiers in Aging Neuroscience, 2022. DOI: 10.3389/fnagi.2022.782282. PMID: 35211004.
• Qudah 2026. Effects of intermittent fasting on HbA1c and weight in insulin versus oral hypoglycemic therapy-treated patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Frontiers in Nutrition, 2026. DOI: 10.3389/fnut.2026.1699384. PMID: 41693941.
• James 2024. Prolonged nightly fasting in older adults with memory decline: A single-group pilot study exploring changes in cognitive function and cardiometabolic risk factors. Journal of Clinical and Translational Science, 2024. DOI: 10.1017/cts.2024.676. PMID: 39830610.
• Wang 2025. The impact of intermittent fasting on body composition and cardiometabolic outcomes in overweight and obese adults: a systematic review and meta-analysis of randomized controlled trials. Nutrition Journal, 2025. DOI: 10.1186/s12937-025-01178-6. PMID: 40731344.
• Sulaj 2025. Periodic fasting induced reconstitution of metabolic flexibility improves albuminuria in patients with type 2 diabetes. Molecular Metabolism, 2025. DOI: 10.1016/j.molmet.2025.102257. PMID: 41005725.
• Liu 2026. Intermittent fasting for rheumatic diseases: a systematic review and meta-analysis of conflicting evidence from observational studies and randomized controlled trials. PeerJ, 2026. DOI: 10.7717/peerj.21185. PMID: 42079723.
• Valenzano 2025. Influence of Intermittent Fasting on Body Composition, Physical Performance, and the Orexinergic System in Postmenopausal Women: A Pilot Study. Nutrients, 2025. DOI: 10.3390/nu17071121. PMID: 40218879.
• Burns 2025. Effects of fasting-mimicking diets with low and high protein content on cardiometabolic health and autophagy: A randomized, parallel group study. Clin Nutr, 2025. DOI: 10.1016/j.clnu.2025.08.004. PMID: 40816210.
• Knight 2024. EFFECTS OF FASTING STATUS ON PLASMA ENDOCRINE BIOMARKERS IN OLDER ADULTS. Innovation in Aging, 2024. DOI: 10.1093/geroni/igae098.2622.
• James 2022. PROLONGED NIGHTLY FASTING AMONG OLDER ADULTS: A PILOT STUDY EXPLORING CHANGES IN COGNITIVE FUNCTION. Innovation in Aging, 2022. DOI: 10.1093/geroni/igac059.2960.
• Couto 2025. The impact of intermittent fasting and Mediterranean diet on older adults' physical health and quality of life: A randomized clinical trial. Nutr Metab Cardiovasc Dis, 2025. DOI: 10.1016/j.numecd.2025.104132. PMID: 40451678.
• Grant 2025. A Novel Fasting Mimetic (Mimio™) Improves Hunger, Digestion, Oxidative Stress, and Cardiometabolic Markers in Overweight Adults with Elevated HbA1c: a Double-Blind, Randomized, Placebo-Controlled Trial. medRxiv preprint, 2025. DOI: 10.1101/2025.04.30.25326755.
• Gabriel 2024. Prolonged water-only fasting in the management of low-grade follicular lymphoma: a case series. Journal of Medical Case Reports, 2024. DOI: 10.1186/s13256-024-04609-w. PMID: 38956708.
• Engeland 2024. EFFECTS OF FASTING STATUS ON BLOOD-BASED INFLAMMATORY BIOMARKERS IN OLDER ADULTS. Innovation in Aging, 2024. DOI: 10.1093/geroni/igae098.2620.
• Engeland 2024b. EFFECTS OF FASTING STATUS ON BLOOD-BASED NEURODEGENERATIVE BIOMARKERS IN OLDER ADULTS. Innovation in Aging, 2024. DOI: 10.1093/geroni/igae098.2621.

Background References

Canonical clinical thresholds cited in prose. Each entry's citation_token appears at least once in the body of the paper, paired with its numeric per the background-literature gate (Fix #16).

• Studenski 2011. Studenski S, Perera S, Patel K, et al. Gait speed and survival in older adults. JAMA. 2011;305(1):50-58. DOI: 10.1001/jama.2010.1923. PMID: 21205966.
• ADA 2024. American Diabetes Association. Standards of Care in Diabetes. Diabetes Care. 2024;47(Suppl 1). DOI: 10.2337/dc24-S006.
• Bohannon 1997. Bohannon RW. Comfortable and maximum walking speed of adults aged 20-79 years: reference values and determinants. Age Ageing. 1997;26(1):15-19. DOI: 10.1093/ageing/26.1.15.
• Cruz-Jentoft 2019. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16-31. DOI: 10.1093/ageing/afy169. PMID: 30312372.
• Schulz 2010. Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332. DOI: 10.1136/bmj.c332.
• Ioannidis 2005. Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124. DOI: 10.1371/journal.pmed.0020124. PMID: 16060722.